ArticleWorld journal of surgical oncology2025
The combination of CA125, CA199, CEA, and AFP is an effective diagnostic biomarker for gastric cancer in elderly individuals.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Associations of Multiple Serum Tumor Markers with Radiological Response and Overall Survival in Patients with Advanced Gastric Cancer Receiving First-Line Palliative Systemic Therapy.Journal of clinical medicine · 2026Article
- Liposomal honokiol attenuates dimethylhydrazine-induced colon carcinogenesis in rats through modulation of oxidative stress, inflammation, apoptosis, autophagy, and lipid metabolism pathways.Medical oncology (Northwood, London, England) · 2026Article
- MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axis.Translational oncology · 2026Article
- Dual-positive gastric cancer co-expressing AFP and CEA: an aggressive subtype defined by unique clinical and biological profiles.Clinical and experimental medicine · 2026Review
- Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.Frontiers in oncology · 2026Review
- Potential function of miRNA as a diagnostic biomarker for human ovarian cancer.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum tumour markers (TMs) such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and CA125 have been established as prognostic indicators for gastric cancer (GC); however, the diagnostic value of these markers for GC in older adults has yet to be examined. Therefore, this study aimed to explore the diagnostic and prognostic significance of AFP, CEA, CA199 and CA125 for GC in elderly individuals.
methodsA total of 188 patients who visited The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, from May 2021 to March 2024 were selected for this study. TMs, namely, CA199, CA125, CEA, and AFP, were examined in all patients. Comparisons of these TMs were conducted among the three groups, and TM levels were compared in patients with GC at various TNM stages. The diagnostic value of these TMs for GC was evaluated by calculating the area under the curve (AUC).
resultsWe selected 89 patients diagnosed with GC: 52 patients with benign gastric diseases and 47 healthy individuals for our study. The positivity rates of AFP, CA125, CEA and CA199 were significantly greater in the GC group (31.46%, 31.46%, 43.82% and 23.60%, respectively) than in the benign gastric disease group and healthy control group. The diagnostic sensitivities of CEA, CA125, CA199 and AFP for GC were 31.46%, 29.21%, 44.90% and 24.72%, respectively. The combination of these markers yielded a sensitivity of 65.17%, which was significantly greater than the sensitivity of each marker alone (P < 0.05). Additionally, patients with stage I-II disease had significantly lower serum levels of CEA, CA199, CA125, and AFP than did those with stage III-IV disease.
conclusionsThe levels of serum TMs, including CA12-5, CEA, CA199 and AFP, are elevated in elderly individuals with GC, indicating a higher TNM stage. The combination of CEA, CA12-5, CA199 and AFP has enhanced diagnostic value for GC, thereby offering significant clinical guidance. However, this study is limited by its retrospective design and lack of external validation, which should be addressed in future prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.